A phase III study to compare the efficacy and safety of CHS-1420 versus Humira in subjects with rheumatoid arthritis

Trial Profile

A phase III study to compare the efficacy and safety of CHS-1420 versus Humira in subjects with rheumatoid arthritis

Planning
Phase of Trial: Phase III

Latest Information Update: 23 Jan 2015

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Coherus Biosciences
  • Most Recent Events

    • 23 Jan 2015 New trial record
    • 15 Dec 2014 Coherus BioSciences plans to initiate this study during the first half of 2015 to support the planned filing of a marketing application in the USA in 2016 and the EU in 2017, according to Coherus BioSciences SEC filing report 10-Q 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top